Special Issue

Reactive Oxygen Species and Metabolic Dysregulation: From Bench to Bedside

Message from the Guest Editors

Cellular alterations in energy metabolism and metabolic reprogramming are considered hallmarks of diverse diseases including cancer, neurodegenerative diseases, and metabolic disorders like metabolic syndrome and diabetes. An altered cellular metabolism has been recognized as one of the hallmarks of cancer, since malignant cells can divert flux through their metabolic pathways (glycolysis, pentose phosphate pathway, Krebs cycle, etc.) to increase macromolecule and organelle biosynthesis and maintain cellular proliferation. Recent research has associated some of these metabolic changes, particularly in mitochondria, to the production of reactive oxygen species (ROS), reactive oxygen by-products with strong oxidation and signaling functions. This Special Issue welcomes submissions of original research and reviews from diverse areas of cellular biology and biomedical research fields concerned with metabolic and ROS functions and alterations in human diseases, with the purpose of stimulating intriguing perspectives in the discipline.

Guest Editors

Dr. Paola Maycotte
Dr. Álvaro Marín-Hernández
Prof. Dr. Annie Joubert

Deadline for manuscript submissions

15 July 2026

Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/si/265108

Metabolites
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
metabolites@mdpi.com

mdpi.com/journal/metabolites



Metabolites

an Open Access Journal by MDPI

Impact Factor 3.7
CiteScore 6.9
Indexed in PubMed

mdpi.com/journal/metabolites

MDPI

About the Journal

Message from the Editor-in-Chief

The metabolome is the result of the combined effects of genetic and environmental influences on metabolic processes. Metabolomic studies can provide a global view of metabolism and thereby improve our understanding of the underlying biology. Advances in metabolomic technologies have shown utility for elucidating mechanisms which underlie fundamental biological processes including disease pathology. *Metabolites* is proud to be part of the development of metabolomics and we look forward to working with many of you to publish high quality metabolomic studies.

Editor-in-Chief

Dr. Amedeo Lonardo
Internal Medicine, Ospedale Civile di Baggiovara, Azienda Ospedaliero-Universitaria, 41126 Modena, Italy

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q2 (Endocrinology, Diabetes and Metabolism)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.4 days after submission; acceptance to publication is undertaken in 3.6 days (median values for papers published in this journal in the first half of 2025).